Page 1 of Clinical Trials for ( Adjuvants AND Immunologic ), 2867 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Recruiting
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Last Updated: March 19, 2012
Condition(s): Sarcoma
2
Completed
GM-CSF as Adjuvant Therapy of Melanoma
Last Updated: July 10, 2006
Condition(s): Malignant Melanoma
3
Active, not recruiting
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
Last Updated: January 6, 2012
Condition(s): Melanoma
4
Terminated
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Last Updated: October 14, 2010
Condition(s): Melanoma
5
Completed
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Last Updated: May 3, 2012
Condition(s): HIV Infections
6
Active, not recruiting
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma
Last Updated: December 8, 2011
Condition(s): Neuroblastoma
7
Recruiting
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Last Updated: August 29, 2011
Condition(s): Melanoma
8
Completed
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21
Last Updated: January 27, 2012
Condition(s): Prostate Cancer
9
Completed
PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection
Last Updated: June 18, 2010
Condition(s): HIV Infection
10
Completed
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Last Updated: December 14, 2011
Condition(s): Intraocular Melanoma; Malignant Conjunctival Neoplasm; Melanoma (Skin)
11
Active, not recruiting
H5N1 Mix and Match With AS03
Last Updated: May 17, 2012
Condition(s): Influenza
12
Completed
Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Last Updated: January 6, 2012
Condition(s): Prostate Cancer
13
Completed
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Last Updated: May 22, 2012
Condition(s): HIV Infections
14
Completed
A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Last Updated: April 27, 2012
Condition(s): HIV Infections; HIV Seronegativity
15
Completed
Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Last Updated: June 23, 2005
Condition(s): HIV Infections
16
Completed
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
Last Updated: May 23, 2012
Condition(s): HIV Infections
17
Active, not recruiting
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
Last Updated: October 15, 2009
Condition(s): Melanoma
18
Active, not recruiting
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome
Last Updated: February 26, 2009
Condition(s): Myelodysplastic Syndromes
19
Recruiting
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
Last Updated: September 14, 2009
Condition(s): Tuberculosis
20
Completed
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Last Updated: May 23, 2012
Condition(s): HIV Infections

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Adjuvants%2C+Immunologic

Page 1 of Clinical Trials for ( Adjuvants AND Immunologic ), 2867 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About